190 related articles for article (PubMed ID: 28063020)
1. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
[TBL] [Abstract][Full Text] [Related]
2. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Zazo H; Martín-Suárez A; Lanao JM
Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
[TBL] [Abstract][Full Text] [Related]
4. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
[TBL] [Abstract][Full Text] [Related]
6. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.
Nolt VD; Pijut KD; Autry EB; Williams WC; Burgess DS; Burgess DR; Arora V; Kuhn RJ
Pediatr Pulmonol; 2019 Jan; 54(1):33-39. PubMed ID: 30507069
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
[TBL] [Abstract][Full Text] [Related]
8. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
Halacová M; Průsa R; Kotaska K; Vávrová V
Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
[TBL] [Abstract][Full Text] [Related]
10. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
[TBL] [Abstract][Full Text] [Related]
11. Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.
Alhadab AA; Ahmed MA; Brundage RC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358293
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
So W; Crandon JL; Hamada Y; Nicolau DP
J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
[TBL] [Abstract][Full Text] [Related]
13. A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis.
Woillard JB; Bouchet S; Fayon M; Marquet P; Monchaud C; Bui S
Ther Drug Monit; 2021 Aug; 43(4):499-504. PubMed ID: 33346630
[TBL] [Abstract][Full Text] [Related]
14. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
[TBL] [Abstract][Full Text] [Related]
18. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
20. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
